Better late than early: FDG-PET imaging in metastatic renal cell carcinoma.
Journal Article (Journal Article)
Sunitinib treatment benefits patients with metastatic renal cell carcinoma (mRCC), but response duration can vary widely and resistance is not predicted by standard measures. [¹⁸F]fluoro-2-deoxy-2-D-glucose positron emission tomography (FDG-PET) uptake is variable in mRCC, but changes in FDG-PET uptake may be useful in monitoring disease progression. Further work is needed to personalize treatment for patients with mRCC.
Full Text
Duke Authors
Cited Authors
- Harrison, MR; George, DJ
Published Date
- September 15, 2011
Published In
Volume / Issue
- 17 / 18
Start / End Page
- 5841 - 5843
PubMed ID
- 21926167
Electronic International Standard Serial Number (EISSN)
- 1557-3265
Digital Object Identifier (DOI)
- 10.1158/1078-0432.CCR-11-1768
Language
- eng
Conference Location
- United States